[Skip to Content]
[Skip to Content Landing]
Views 660
Citations 0
Research Letter
June 3, 2019

Public Disclosure of the Filing of New Drug and Therapeutic Biologics Applications With the US Food and Drug Administration

Author Affiliations
  • 1Office of Public Health Strategy and Analysis, Office of the Commissioner, US Food and Drug Administration, Silver Spring, Maryland
  • 2Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, New Brunswick
  • 3Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland
  • 4Center for Science in the Public Interest, Washington, DC
JAMA Intern Med. 2019;179(8):1144-1146. doi:10.1001/jamainternmed.2019.1213

Current regulations prohibit the US Food and Drug Administration (FDA) from publicly disclosing the existence of pending New Drug Applications (NDAs) or Biologics License Applications (BLAs) unless previously publicly disclosed or acknowledged.1 Applicants may disclose applications in press releases, Securities and Exchange Commission (SEC) filings, or in other media; how frequently they do so is not known.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words